Jane Street
RNAC icon

Jane Street’s Cartesian Therapeutics RNAC Stock Holding History

Jane Street’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Buy
+13,600
New +$101K ﹤0.01% 10390
2021
Q3 		– Sell
-1,957
Closed -$245K – 10598
2021
Q2 		$245K Buy
+1,957
New +$233K ﹤0.01% 8501

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jane Street's RNAC Position: Q2 2026 in Review

Jane Street opened a new position in Cartesian Therapeutics (RNAC) in Q2 2026: 11,824 shares worth $123K. The stake represents ﹤0.01% of the portfolio and ranks #10484 among its holdings. This is a return to the name: Jane Street previously reported a position in RNAC as recently as Q1 2024.

Jane Street first reported a position in RNAC in Q2 2019 and has held it in 16 quarters since. The position peaked at $478K in Q2 2020. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Jane Street held 11,824 shares of Cartesian Therapeutics worth $123K as of Q2 2026.
  • Cartesian Therapeutics was a new Jane Street position in Q2 2026.
  • Cartesian Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10484 holding.
  • Jane Street first reported a position in Cartesian Therapeutics in Q2 2019 and has held it in 16 quarters since.
  • Jane Street's Cartesian Therapeutics position peaked at $478K in Q2 2020.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.